JP2014511866A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014511866A5 JP2014511866A5 JP2014504086A JP2014504086A JP2014511866A5 JP 2014511866 A5 JP2014511866 A5 JP 2014511866A5 JP 2014504086 A JP2014504086 A JP 2014504086A JP 2014504086 A JP2014504086 A JP 2014504086A JP 2014511866 A5 JP2014511866 A5 JP 2014511866A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- chimeric polypeptide
- fragment
- par2
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 51
- 229920001184 polypeptide Polymers 0.000 claims 41
- 102000004196 processed proteins & peptides Human genes 0.000 claims 41
- 102000032628 PAR-2 Receptor Human genes 0.000 claims 22
- 108010070503 PAR-2 Receptor Proteins 0.000 claims 22
- 239000012634 fragment Substances 0.000 claims 22
- 230000035772 mutation Effects 0.000 claims 19
- 102000002020 Protease-activated receptors Human genes 0.000 claims 18
- 108050009310 Protease-activated receptors Proteins 0.000 claims 18
- 150000001413 amino acids Chemical class 0.000 claims 14
- 125000000539 amino acid group Chemical group 0.000 claims 10
- 108010070519 PAR-1 Receptor Proteins 0.000 claims 8
- 102100037136 Proteinase-activated receptor 1 Human genes 0.000 claims 8
- 230000002209 hydrophobic effect Effects 0.000 claims 8
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 7
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 7
- 230000003834 intracellular effect Effects 0.000 claims 7
- 238000006467 substitution reaction Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 101001086405 Bos taurus Rhodopsin Proteins 0.000 claims 2
- 150000008574 D-amino acids Chemical class 0.000 claims 2
- 101000613565 Homo sapiens PRKC apoptosis WT1 regulator protein Proteins 0.000 claims 2
- 101001135199 Homo sapiens Partitioning defective 3 homolog Proteins 0.000 claims 2
- 101001098557 Homo sapiens Proteinase-activated receptor 3 Proteins 0.000 claims 2
- 101001113471 Homo sapiens Proteinase-activated receptor 4 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100037133 Proteinase-activated receptor 3 Human genes 0.000 claims 2
- 102100023710 Proteinase-activated receptor 4 Human genes 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000816 peptidomimetic Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 206010051113 Arterial restenosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022998 Irritability Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000035268 Mast Cell Activation disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 150000003855 acyl compounds Chemical class 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 102000050100 human F2RL1 Human genes 0.000 claims 1
- 206010021198 ichthyosis Diseases 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000004941 influx Effects 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 210000002752 melanocyte Anatomy 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 125000001360 methionine group Chemical class N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000004994 reproductive system Anatomy 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161473675P | 2011-04-08 | 2011-04-08 | |
| US61/473,675 | 2011-04-08 | ||
| PCT/US2012/032824 WO2012139137A2 (en) | 2011-04-08 | 2012-04-09 | Pepducin design and use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014511866A JP2014511866A (ja) | 2014-05-19 |
| JP2014511866A5 true JP2014511866A5 (cg-RX-API-DMAC7.html) | 2015-05-28 |
| JP6225104B2 JP6225104B2 (ja) | 2017-11-01 |
Family
ID=46969875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014504086A Expired - Fee Related JP6225104B2 (ja) | 2011-04-08 | 2012-04-09 | ペプデューシンの設計および使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10913781B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3351641A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6225104B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012239880B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2832115C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012139137A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3351641A1 (en) | 2011-04-08 | 2018-07-25 | Tufts Medical Center, Inc. | Pepducin design and use |
| CN105517562B (zh) * | 2013-04-05 | 2018-12-28 | 拜欧马可医药公司 | 转移抑制剂 |
| HK1223096A1 (zh) | 2013-09-25 | 2017-07-21 | Vertex Pharmaceuticals Incorporated | 用作par-2信號通路抑制劑的咪唑並噠嗪 |
| ES2984663T3 (es) | 2015-11-13 | 2024-10-30 | Oasis Pharmaceuticals Llc | Moduladores del receptor 2 activados por proteasa |
| ES2909709T3 (es) * | 2016-05-12 | 2022-05-10 | Heptares Therapeutics Ltd | Inhibidores del receptor 2 activado por proteasa |
| AU2020250933A1 (en) | 2019-04-05 | 2021-10-28 | Centre Hospitalier Régional Et Universitaire De Brest | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning |
| KR102268589B1 (ko) * | 2019-04-29 | 2021-06-24 | 사회복지법인 삼성생명공익재단 | 단백질분해효소 활성 수용체 매개 신호전달 경로의 활성을 이용한 세포외 소포의 고효율 생성능을 갖는 줄기세포의 선별방법 |
| EP4595983A1 (en) * | 2024-02-05 | 2025-08-06 | BXTA Nanotherapy Limited | Nanoparticles functionalised with a stabilising agent and a targeting agent |
| WO2025172573A1 (en) | 2024-02-16 | 2025-08-21 | Domain Therapeutics | Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9266930B1 (en) | 1993-03-05 | 2016-02-23 | Epimmune Inc. | Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions |
| EP0835928A1 (en) | 1996-10-11 | 1998-04-15 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | Helicobacter pylori live vaccine |
| US7368531B2 (en) | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
| US6747137B1 (en) | 1998-02-13 | 2004-06-08 | Genome Therapeutics Corporation | Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics |
| US6815200B1 (en) | 1998-02-17 | 2004-11-09 | The Uab Research Foundation | Modified adenovirus containing a fiber replacement protein |
| NZ530277A (en) | 1998-04-07 | 2005-08-26 | Medimmune Inc | Derivatives of pneumococcal choline binding proteins for vaccines |
| US6562958B1 (en) | 1998-06-09 | 2003-05-13 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics |
| US6228989B1 (en) * | 1998-11-13 | 2001-05-08 | The Regents Of The University Of California | Peptide substrates phosphorylated by P21-activated protein kinase |
| WO2000034469A1 (en) | 1998-12-11 | 2000-06-15 | The Research Foundation Of State University Of New York At Albany | Compositions and methods for altering cell migration |
| US6703491B1 (en) | 1999-03-17 | 2004-03-09 | Exelixis, Inc. | Drosophila sequences |
| US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| WO2001081408A2 (en) * | 2000-04-21 | 2001-11-01 | New England Medical Center | G-protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same |
| US7696168B2 (en) | 2000-04-21 | 2010-04-13 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same |
| US6773893B1 (en) | 2000-04-28 | 2004-08-10 | The Trustees Of Columbia University In The City Of New York | Human ABC1 promoter and assays based thereon |
| US7834146B2 (en) | 2000-05-08 | 2010-11-16 | Monsanto Technology Llc | Recombinant polypeptides associated with plants |
| EP1197755A1 (en) | 2000-10-11 | 2002-04-17 | Pepscan Systems B.V. | Identification of protein binding sites |
| US7214786B2 (en) | 2000-12-14 | 2007-05-08 | Kovalic David K | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| WO2004012681A2 (en) | 2002-08-02 | 2004-02-12 | South Alabama Medical Sciences Foundation | Cancer vaccines containing epitopes of oncofetal antigen |
| WO2004022576A2 (en) | 2002-09-03 | 2004-03-18 | Children's Hospital | Short peptides from the '2nd loop' of 7 transmembrane receptor which selectively modulate signal transduction |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| WO2004067712A2 (en) * | 2003-01-22 | 2004-08-12 | Incyte Corporation | Intracellular signaling molecules |
| US7189691B2 (en) | 2004-04-01 | 2007-03-13 | The Administrators Of The Tulane Educational Fund | Methods and compositions for treating leukemia |
| US20070207209A1 (en) | 2004-08-27 | 2007-09-06 | Murphy Christopher J | Trophic factor combinations for nervous system treatment |
| US7319142B1 (en) | 2004-08-31 | 2008-01-15 | Monsanto Technology Llc | Nucleotide and amino acid sequences from Xenorhabdus and uses thereof |
| US8440627B2 (en) | 2004-11-04 | 2013-05-14 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of use |
| US8088976B2 (en) | 2005-02-24 | 2012-01-03 | Monsanto Technology Llc | Methods for genetic control of plant pest infestation and compositions thereof |
| WO2007061850A2 (en) | 2005-11-17 | 2007-05-31 | Massachusetts Institute Of Technology | Methods and systems for generating and evaluating peptides |
| DK1987178T3 (en) | 2006-02-20 | 2015-04-20 | Phylogica Ltd | Process for the construction and screening of peptide structure libraries |
| CA2660286A1 (en) | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| WO2008144753A2 (en) | 2007-05-21 | 2008-11-27 | Alder Biopharmaceuticals, Inc. | Antibodies to tnf alpha and use thereof |
| JP4400668B2 (ja) | 2007-11-01 | 2010-01-20 | 株式会社豊田中央研究所 | 微小物体が固定化された固相体の製造方法及びその利用 |
| WO2009099580A2 (en) | 2008-02-05 | 2009-08-13 | Monsanto Technology, Llc | Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits |
| EP2362779A4 (en) | 2008-11-04 | 2013-03-20 | Anchor Therapeutics Inc | CXCR4 RECEPTOR COMPOUNDS |
| RU2011122482A (ru) | 2008-11-04 | 2012-12-20 | Энкер Терапьютикс, Инк. | Apj-рецепторы соединения |
| US8303962B2 (en) | 2009-01-06 | 2012-11-06 | C3 Jian, Inc. | Antibacterial and antifungal peptides |
| US9012723B2 (en) | 2009-01-16 | 2015-04-21 | Monsanto Technology Llc | Isolated novel acid and protein molecules from soy and methods of using those molecules to generate transgene plants with enhanced agronomic traits |
| US8389679B2 (en) | 2009-02-05 | 2013-03-05 | The Regents Of The University Of California | Targeted antimicrobial moieties |
| JP2012523438A (ja) * | 2009-04-10 | 2012-10-04 | タフツ メディカル センター インコーポレイテッド | メタロプロテイナーゼ−1(mmp−1)によるpar−1活性化 |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| EP3351641A1 (en) | 2011-04-08 | 2018-07-25 | Tufts Medical Center, Inc. | Pepducin design and use |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
-
2012
- 2012-04-09 EP EP17199261.3A patent/EP3351641A1/en not_active Withdrawn
- 2012-04-09 AU AU2012239880A patent/AU2012239880B2/en not_active Ceased
- 2012-04-09 CA CA2832115A patent/CA2832115C/en not_active Expired - Fee Related
- 2012-04-09 EP EP12767963.7A patent/EP2697386B1/en not_active Not-in-force
- 2012-04-09 JP JP2014504086A patent/JP6225104B2/ja not_active Expired - Fee Related
- 2012-04-09 US US14/009,479 patent/US10913781B2/en active Active
- 2012-04-09 WO PCT/US2012/032824 patent/WO2012139137A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010202328B2 (en) | G Protein Coupled Receptor Agonists and Antagonists and Methods of Use | |
| US10253080B2 (en) | Glucagon-like-peptide-2 (GLP-2) analogues | |
| US10092648B2 (en) | Selective glucagon-like-peptide-2 (GLP-2) analogues | |
| ES2984663T3 (es) | Moduladores del receptor 2 activados por proteasa | |
| BR112015010203B1 (pt) | uso de uma composição para a preparação de um medicamento para a prevenção ou o tratamento de diabetes, complicações diabéticas ou diabesidade compreendendo um conjugado analogo da oxintomodulina | |
| JP2011526303A5 (cg-RX-API-DMAC7.html) | ||
| US9731007B2 (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| JP2018537529A5 (cg-RX-API-DMAC7.html) | ||
| WO2022238510A1 (en) | Therapeutic derivatives of interleukin-22 | |
| JP2013535965A5 (cg-RX-API-DMAC7.html) | ||
| ES2575517T3 (es) | Péptidos de unión a FGF2 y usos de los mismos | |
| AU2020299636A1 (en) | Compositions and methods of use | |
| JP2005213160A (ja) | Fas作動性アポトーシス調節ペプチドとその用途 |